Navigation Links
GDFII/L&P Confirms Target Date Extension Of U.S. ITC Sucralose Ruling
Date:3/26/2009

Leading Sucralose manufacturer Guangdong Food Industry Institute/L&P Food Ingredient Co. Ltd. (GDFII/L&P) today announced that the U.S. International Trade Commission (ITC) in Washington D.C. has extended the target date of its final decision in the sucralose case, from March 25 to April 3. This Section 337 patent dispute (docket# 337-TA-604) was filed against the company by its main competitor, Tate & Lyle Corporation (T&L)

Exeter, California (PRWEB) March 26, 2009 -- Leading Sucralose manufacturer Guangdong Food Industry Institute/L&P Food Ingredient Co. Ltd. (GDFII/L&P) today announced that the U.S. International Trade Commission (ITC) in Washington D.C. has extended the target date of its final decision in the sucralose case, from March 25 to April 3. This Section 337 patent dispute (docket# 337-TA-604) was filed against the company by its main competitor, Tate & Lyle Corporation (T&L).

"GDFII/L&P was the first company to manufacture sucralose outside of the U.S.A and continues to be committed to meeting its customer needs of high capacity and superior grade sucralose in the growing sucralose market in the United States and elsewhere, and remains confident of a positive outcome once the ITC issues its final determination," notes Mr. Sanyong Wang, a corporate officer of GDFII/L&P.

Mr. Bassam Faress, spokesperson of GDFII/L&P and Director of Sales/Marketing at Ingredients Specialties, Inc., a global alliance partner of GDFII/L&P, adds "we continue to look forward to this anticipated positive final ruling as we move ahead with our strategic marketing and expansion plans for Sucralose."

The U.S. ITC governs investigations into allegations of unfair trade practices and had in its September 2008 initial determination issued by Administrative Law Judge Charles E. Bullock of the ITC, noted that GDFI
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2

Related biology technology :

1. Mylan Confirms Four First-to-File Challenges
2. Amylin Pharmaceuticals Confirms Receipt of Director Nomination Notices
3. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
4. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
5. Barr Confirms Patent Challenge of Sensipar(R) Tablets, 30mg, 60mg and 90mg
6. Brazilian Sugarcane Industry: OECD Report Confirms Overall Benefits of Brazilian Sugarcane Ethanol
7. ATS Medical Confirms Excellent Durability of the ATS Open Pivot Mechanical Heart Valve
8. Superior Patient Clinical Outcomes Confirms DaVitas Leadership Position on Quality Dialysis Care
9. ProMetic Further Confirms Performance of Prion Capture Resin at the Recovery of Biological Products Conference
10. Barr Confirms Patent Challenge of Prevacid(R) SoluTab(TM) Delayed-Release Orally Disintegrating Tablets, 15mg and 30mg
11. Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
GDFII/L&P Confirms Target Date Extension Of U.S. ITC Sucralose Ruling
(Date:9/18/2014)... NY (PRWEB) September 18, 2014 Whitehouse ... negotiations with Salem Realty Group and has acquired an ... space within the Salem Executive Complex adjacent to its ... was held on Friday September 5th. Whitehouse Labs is ... the entire space specifically for package testing. The prime ...
(Date:9/17/2014)... Sept. 17, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ... offer and sell shares of its Common Stock and ... underwritten public offerings.  The Series A Convertible Preferred Stock ... Stock, provided that conversion will be prohibited if, as ... own more than 4.99% of the Common Stock then ...
(Date:9/17/2014)... , Sept. 17, 2014  MiMedx Group, Inc. (NASDAQ: ... and marketer of patent protected regenerative biomaterials and ... publication of another peer-reviewed clinical study.    ... Multi-center Randomized Controlled Clinical Trial Evaluating the Use ... Allografts and Multi-layer Compression Therapy vs. Multi-layer Compression ...
(Date:9/17/2014)... 17, 2014 Immunomic Therapeutics, Inc. announced ... (SBIR) grant to support the continued preclinical development of ... with approximately $255,000 over one year to conduct vaccine ... food allergy, affect over one million Americans and are ... Tree nut exposure is also a risk for peanut ...
Breaking Biology Technology:Whitehouse Labs Announces Package Testing Laboratory Expansion 2Whitehouse Labs Announces Package Testing Laboratory Expansion 3Whitehouse Labs Announces Package Testing Laboratory Expansion 4Oncothyreon Announces Proposed Public Offerings 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 4Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3
... 2011 Amylin Pharmaceuticals, Inc. (Nasdaq: ... for 2011, highlighting its continued focus on strong ... Company,s diabetes franchise, notably through advancing the investigational ... other value-driving development programs. Daniel M. Bradbury, president ...
... BioLife Solutions, Inc. (OTC Bulletin Board: BLFS ) ... and Chief Executive Officer Mike Rice, to summarize the continued ... strategic growth initiatives.   (Logo:   http://photos.prnewswire.com/prnh/20090814/BIOLIFELOGO ) ... of $575,000 for the fourth quarter of 2010, an increase ...
... The Jackson Laboratory (JAX), Sackler School of Graduate Biomedical Sciences ... a new mammalian genetics track for Ph.D. students. The joint ... and Tufts. Combining the faculty and resources of the genetics ... the faculty and resources at JAX, with its emphasis on ...
Cached Biology Technology:Amylin to Advance Key Value-Driving Opportunities in 2011 2Amylin to Advance Key Value-Driving Opportunities in 2011 3BioLife Solutions CEO Issues 2010 Corporate Update 2BioLife Solutions CEO Issues 2010 Corporate Update 3The Jackson Laboratory and Tufts University Announce New Ph.D. Track in Mammalian Genetics 2The Jackson Laboratory and Tufts University Announce New Ph.D. Track in Mammalian Genetics 3
(Date:9/17/2014)... have obtained the first partial genome sequence of an ... at the site of the Montsoriu Castle in Girona, ... closely related to today,s Iberian pig. Researchers also discard ... Iberian pigs. , The study, published in Heredity ... species, and particularly on that of the Iberian breed, ...
(Date:9/17/2014)... September 17, 2014 Researchers at UTSouthwestern Medical ... the circulating protein apolipoprotein E, called apoE3, helps repair ... called apoE4, do not get the benefit of this ... , "We believe that we have identified one mechanism ... why a genetic variant, apoE4, is detrimental," said ...
(Date:9/17/2014)... 1960s. The typical development phases of trees and stands ... as much as 70 percent. This was the outcome ... Universitt Mnchen based on long-term data from experimental forest ... findings were published recently in Nature Communications . ... topic, with the very survival of large forest ecosystems ...
Breaking Biology News(10 mins):Iberian pig genome remains unchanged after 5 centuries 2Protein variant may boost cardiovascular risk by hindering blood vessel repair 2Global change: Trees continue to grow at a faster rate 2Global change: Trees continue to grow at a faster rate 3
... is available in German . , ... , is able to rapidly ,and efficiently detoxify chemical ... the Tokyo subway attacks in 1995. A detailed understanding ... is ,necessary for efforts aiming to improve their properties. ...
... of Canada,s southern Rockies are a more distinct breed ... by University of Calgary researchers that is shedding light ... In a study published in the current issue of ... Design PhD candidate Byron Weckworth and his research group ...
... release is available in French . ... is pleased to announce that Concordia,s Centre for Structural ... research done by nine universities which are part of ... focusing on the conversion of agricultural waste into biofuel ...
Cached Biology News:Structure of enzyme against chemical warfare agents determined 2Mountain caribou's ancient ancestry revealed 2
... offers major advantages over other RNA precipitation methods ... or carbohydrates. It is the method of choice ... from RNA preparations. Note, LiCl precipitation may not ... If the RNA is to be used for ...
... Antifade Kit is an aqueous-based mounting reagent ... dyes. This formulation of antifade minimizes the ... Blue fluorophores that is often seen with ... available with the blue-fluorescent nucleic acid ...
in vitro Translation, Accessory Products...
Mouse Collagen IV...
Biology Products: